Monday, April 11, 2011

Adalimumab

Introduction:

It is a fully human recombinant monoclonal antibody (MAB).

Mechanism of action:
It gets bind to human TNF-α receptor site thus stops endogenous TNF- α activity by preventing its interaction with p55 and p75 cell surface receptors.

Action:
It decreases symptoms of Rheumatoid arthritis and stops erosion of the (bone) structure.

Therapeutic uses:
It is used in Rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis. (As increased TNF in the synovial fluid cause pain and joint destruction in Rheumatoid arthritis).

Pharmacokinetics:
It is used subcutaneously and its half life is 10-20 days.

Dose and Administration:
Its usual dose is 40 mg every other week. It is used Subcutaneously only.

Adverse effects:
It may cause headache, nausea, rashes and reactions at the site of injection.
Post a Comment